Empowered Funds’s Theravance Biopharma TBPH Stock Holding History

Empowered Funds’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-55,463	Closed	-$900K	–	2283
2026 Q1	$900K	Buy	+55,463	New	+$981K	0.01%	1445

Other funds holding TBPH

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

ICM

Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Empowered Funds's TBPH Position: Q2 2026 in Review

Empowered Funds sold out of Theravance Biopharma (TBPH) in Q2 2026, closing a stake of 55,463 shares — an estimated $900K sold.

Empowered Funds first reported a position in TBPH in Q1 2026 and held it in 1 quarter. The position peaked at $900K in Q1 2026. 181 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

Empowered Funds reported no remaining Theravance Biopharma position as of Q2 2026 after selling out during the quarter.
Empowered Funds sold 55,463 Theravance Biopharma shares in Q2 2026, an estimated $900K.
Empowered Funds first reported a position in Theravance Biopharma in Q1 2026 and held it in 1 quarter.
Empowered Funds's Theravance Biopharma position peaked at $900K in Q1 2026.
181 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Empowered Funds's 13F filing for Q2 2026, filed 17 Aug 2026.